Pharmacology

Action Mechanism of Action Reference
INHIBITOR Killer cell immunoglobulin-like receptor 2DL1 inhibitor PMC PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leukemia 2 D007938 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Hodgkin Disease 1 D006689 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials
Urinary Bladder Neoplasms 1 D001749 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1000676-41-4
ChEMBL CHEMBL2109500
FDA SRS S9XDI9W918
Guide to Pharmacology 9310